Stay updated on Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Sign up to get notified when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.

Latest updates to the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 has been added; older Revision: v3.4.1 and the government funding notice have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedSite-wide maintenance notices were added regarding a lapse in government funding and NIH Clinical Center status, and the page revision tag updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary display is now shown; metadata lines updated to 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0' replacing the previous lowercase variants and earlier revision.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no study content or data were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a dedicated Locations section with Georgia as a location, and updated the page revision to v3.3.3. Removed the separate Georgia Locations header and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check92 days agoChange DetectedNon-significant editorial changes were made, including notes that publications are provided voluntarily and may be auto-filled from PubMed and the addition of a Revision: v3.3.2 label; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lymphodepletion & Anti-PD-1 to Reduce AML Relapse Clinical Trial page.